{"id":33066,"date":"2014-10-07T11:50:27","date_gmt":"2014-10-07T15:50:27","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=33066"},"modified":"2014-10-07T11:50:27","modified_gmt":"2014-10-07T15:50:27","slug":"cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066","title":{"rendered":"Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/07\/2014 (wallstreetpr) \u2013\u00a0<strong>Cerus Corporation (NASDAQ:CERS)<\/strong>\u2019s clinical protocol for the INTERCEPT Blood System for platelets got <a href=\"http:\/\/www.marketwatch.com\/story\/us-fda-accepts-ide-submission-by-cerus-making-the-intercept-blood-system-available-to-address-chikungunya-and-dengue-blood-safety-risks-2014-10-07?reflink=MW_news_stmp\" target=\"_blank\">accepted<\/a> by the U.S. FDA. The protocol submission was to make the INTERCEPT for available under an Expanded Access IDE (Investigational Device Exemption) to regions with outbreaks of dengue and Chikungunya virus.<\/p>\n<p style=\"text-align: justify;\">This approval will allow use of INTERCEPT in place of bacterial detection, CMV testing and gamma irradiation, and enabling timely release of platelet products with simplified logistics. The company noted that currently there are no licensed tests to diagnose dengue or Chikungunya virus in asymptomatic blood donors. The company has also submitted PMA (Premarket Approval) for INTERCEPT plasma and platelets which are currently under review. The company expects approval decisions for PMA in 2015.<\/p>\n<p style=\"text-align: justify;\"><strong>Protocol Submission to the FDA<\/strong><\/p>\n<p style=\"text-align: justify;\">Cerus Corporation (NASDAQ:CERS) submitted the clinical protocol to the U.S. FDA in September 2014, under the Treatment Use provision. In the absence of satisfactory alternative to treat patients with serious conditions, this provision allows early use of therapy in the U.S., even before their approval.<\/p>\n<p style=\"text-align: justify;\">The company\u2019s SVP of regulatory affairs, Carol Moore expressed that the approval will allow early use of INTERCEPT Blood System for platelets in the U.S. hospitals and blood centers. He also noted that the IDE approval will also allow commencing the first study before the end of this year.<\/p>\n<p style=\"text-align: justify;\"><strong>About INTERCEPT<\/strong><\/p>\n<p style=\"text-align: justify;\">French Antilles blood center uses Cerus Corporation (NASDAQ:CERS)\u2019s INTERCEPT blood system for six years. The system essentially reduces the risk of transfusion-transmitted Chikungunya and dengue virus. Dengue virus is highly prevalent in the Caribbean region, and the local transmission is also reported in Florida and Texas. The CDC has notified 11 cases of locally-transmitted Chikungunya in Florida, 45 cases in the U.S. Virgin Islands and over 400 cases in Puerto Rico, as at September 30, 2014. INTERCEPT platelet system has been approved in Europe for more than a decade and is under review in the U.S. Canada, China and Brazil.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/07\/2014 (wallstreetpr) \u2013\u00a0Cerus Corporation (NASDAQ:CERS)\u2019s clinical protocol for the INTERCEPT Blood System for platelets got accepted by the U.S. FDA. The protocol submission [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":30857,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[3149,10307,3150,10308],"stock_ticker":[],"class_list":["post-33066","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-cerus-corporation-nasdaqcers","tag-intercept-blood-system","tag-nasdaqcers","tag-the-treatment-use-provision","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/07\/2014 (wallstreetpr) \u2013\u00a0Cerus Corporation (NASDAQ:CERS)\u2019s clinical protocol for the INTERCEPT Blood System for platelets got accepted by the U.S. FDA. The protocol submission [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-07T15:50:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Cerus-Corporation.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"276\" \/>\n\t<meta property=\"og:image:height\" content=\"183\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Van Bettauer\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Van Bettauer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066\"},\"author\":{\"name\":\"Van Bettauer\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\"},\"headline\":\"Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System\",\"datePublished\":\"2014-10-07T15:50:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066\"},\"wordCount\":341,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Cerus-Corporation.jpg\",\"keywords\":[\"Cerus Corporation (NASDAQ:CERS)\",\"INTERCEPT Blood System\",\"NASDAQ:CERS\",\"the Treatment Use provision\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066\",\"name\":\"Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Cerus-Corporation.jpg\",\"datePublished\":\"2014-10-07T15:50:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Cerus-Corporation.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Cerus-Corporation.jpg\",\"width\":276,\"height\":183},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\",\"name\":\"Van Bettauer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"caption\":\"Van Bettauer\"},\"description\":\"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066","og_locale":"en_US","og_type":"article","og_title":"Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System - Wall Street PR","og_description":"Boston, MA 10\/07\/2014 (wallstreetpr) \u2013\u00a0Cerus Corporation (NASDAQ:CERS)\u2019s clinical protocol for the INTERCEPT Blood System for platelets got accepted by the U.S. FDA. The protocol submission [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-10-07T15:50:27+00:00","og_image":[{"width":276,"height":183,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Cerus-Corporation.jpg","type":"image\/jpeg"}],"author":"Van Bettauer","twitter_misc":{"Written by":"Van Bettauer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066"},"author":{"name":"Van Bettauer","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d"},"headline":"Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System","datePublished":"2014-10-07T15:50:27+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066"},"wordCount":341,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Cerus-Corporation.jpg","keywords":["Cerus Corporation (NASDAQ:CERS)","INTERCEPT Blood System","NASDAQ:CERS","the Treatment Use provision"],"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066","url":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066","name":"Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Cerus-Corporation.jpg","datePublished":"2014-10-07T15:50:27+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Cerus-Corporation.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Cerus-Corporation.jpg","width":276,"height":183},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cerus-corporation-nasdaqcers-fda-approved-expanded-access-ide-for-intercept-blood-system-33066#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d","name":"Van Bettauer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","caption":"Van Bettauer"},"description":"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/33066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=33066"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/33066\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/30857"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=33066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=33066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=33066"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=33066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}